RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells

RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells

Triple-negative breast cancer (TNBC) stands out as the most aggressive subtype within the spectrum of breast cancer. The current clinical guidelines propose treatment strategies involving cytotoxic agents like epirubicin or paclitaxel. However, the emergence of acquired resistance frequently precipi...

Full description

Bibliographic Details
Main Authors: Fengxu Lv, Wentao Si, Xiaodan Xu, Xiaogang He, Ying Wang, Yetian Li, Feifei Li
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Triple negative breast cancer
Chemoresistance
Cancer stem cells
RUNX2
TGF-β
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558624000046

Internet

http://www.sciencedirect.com/science/article/pii/S1476558624000046

Similar Items